{
    "id": 18915,
    "fullName": "FLT3 D835G",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 D835G lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org, PMID: 11290608). D835G results in autophosphorylation of Flt3 in one study (PMID: 28077790) and therefore, is predicted to lead to a gain of Flt3 protein function.",
            "references": [
                {
                    "id": 2011,
                    "pubMedId": 11290608,
                    "title": "Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11290608"
                },
                {
                    "id": 12457,
                    "pubMedId": 28077790,
                    "title": "FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28077790"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "D835G",
    "createDate": "02/29/2016",
    "updateDate": "10/05/2018",
    "referenceTranscriptCoordinates": {
        "id": 144448,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28018504T>C",
        "cDna": "c.2504A>G",
        "protein": "p.D835G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154).",
            "molecularProfile": {
                "id": 19290,
                "profileName": "FLT3 D835G"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5604,
                    "pubMedId": 26822154,
                    "title": "The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26822154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6458,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154).",
            "molecularProfile": {
                "id": 19290,
                "profileName": "FLT3 D835G"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5604,
                    "pubMedId": 26822154,
                    "title": "The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26822154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19291,
                "profileName": "FLT3 exon 14 ins FLT3 D835G"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19292,
                "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835G"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19290,
            "profileName": "FLT3 D835G",
            "profileTreatmentApproaches": [
                {
                    "id": 19106,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 D835G"
                }
            ]
        },
        {
            "id": 19291,
            "profileName": "FLT3 exon 14 ins FLT3 D835G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19292,
            "profileName": "FLT3 exon 14 ins FLT3 F691L FLT3 D835G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144448,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28018504T>C",
            "cDna": "c.2504A>G",
            "protein": "p.D835G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}